ES2456017T3 - Tratamiento del cáncer con una combinación de un agente que perturba la ruta de señalización de EGF y un oligonucleótido que reduce los niveles de clusterina - Google Patents

Tratamiento del cáncer con una combinación de un agente que perturba la ruta de señalización de EGF y un oligonucleótido que reduce los niveles de clusterina Download PDF

Info

Publication number
ES2456017T3
ES2456017T3 ES05810600.6T ES05810600T ES2456017T3 ES 2456017 T3 ES2456017 T3 ES 2456017T3 ES 05810600 T ES05810600 T ES 05810600T ES 2456017 T3 ES2456017 T3 ES 2456017T3
Authority
ES
Spain
Prior art keywords
clusterin
oligonucleotide
cancer
combination according
antisense
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES05810600.6T
Other languages
English (en)
Spanish (es)
Inventor
Martin Gleave
Gabriella Zupi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of British Columbia
Original Assignee
University of British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of British Columbia filed Critical University of British Columbia
Application granted granted Critical
Publication of ES2456017T3 publication Critical patent/ES2456017T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
ES05810600.6T 2004-11-23 2005-11-22 Tratamiento del cáncer con una combinación de un agente que perturba la ruta de señalización de EGF y un oligonucleótido que reduce los niveles de clusterina Expired - Lifetime ES2456017T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US52294804P 2004-11-23 2004-11-23
US522948P 2004-11-23
US52296004P 2004-11-24 2004-11-24
US522960P 2004-11-24
PCT/CA2005/001775 WO2006056054A1 (en) 2004-11-23 2005-11-22 Treatment of cancer with a combination of an agent that perturbs the egf signaling pathway and an oligonucleotide that reduces clusterin levels

Publications (1)

Publication Number Publication Date
ES2456017T3 true ES2456017T3 (es) 2014-04-21

Family

ID=36497699

Family Applications (1)

Application Number Title Priority Date Filing Date
ES05810600.6T Expired - Lifetime ES2456017T3 (es) 2004-11-23 2005-11-22 Tratamiento del cáncer con una combinación de un agente que perturba la ruta de señalización de EGF y un oligonucleótido que reduce los niveles de clusterina

Country Status (11)

Country Link
US (2) US20080014198A1 (cg-RX-API-DMAC10.html)
EP (1) EP1814595B1 (cg-RX-API-DMAC10.html)
JP (1) JP4980919B2 (cg-RX-API-DMAC10.html)
AU (1) AU2005309274B2 (cg-RX-API-DMAC10.html)
CA (1) CA2584646C (cg-RX-API-DMAC10.html)
DK (1) DK1814595T3 (cg-RX-API-DMAC10.html)
ES (1) ES2456017T3 (cg-RX-API-DMAC10.html)
PL (1) PL1814595T3 (cg-RX-API-DMAC10.html)
PT (1) PT1814595E (cg-RX-API-DMAC10.html)
SI (1) SI1814595T1 (cg-RX-API-DMAC10.html)
WO (1) WO2006056054A1 (cg-RX-API-DMAC10.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ513757A (en) 1999-02-26 2004-12-24 Univ British Columbia Antisense oligonucleotides to inhibit TRPM-2 expression and delay androgen independance in prostatic tumour cells
US7569551B2 (en) * 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
US8710020B2 (en) 2004-04-02 2014-04-29 The University Of British Columbia Clusterin antisense therapy for treatment of cancer
SI1814595T1 (sl) * 2004-11-23 2014-06-30 The University Of British Columbia Zdravljenje raka s kombinacijo sredstva, ki moti EGF signalno pot, in oligonukleotida, ki zniĹľuje nivoje klusterina
ES2543341T3 (es) 2005-09-13 2015-08-18 National Research Council Of Canada Métodos y composiciones para modular la actividad de células tumorales
CA2928846A1 (en) 2009-11-24 2011-06-03 Alethia Biotherapeutics Inc. Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume
RU2013145869A (ru) 2011-03-15 2015-04-20 Дзе Юниверсити Оф Бритиш Коламбиа КОМБИНАЦИЯ ОЛИГОНУКЛЕОТИДА АНТИ-КЛАСТЕРИНА С ИНГИБИТОРОМ Hsp90 ДЛЯ ЛЕЧЕНИЯ РАКА ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ
CA2862739A1 (en) 2012-02-22 2013-08-29 Alethia Biotherapeutics Inc. Co-use of a clusterin inhibitor with an egfr inhibitor to treat cancer
MD20140101A2 (ro) * 2013-02-22 2015-02-28 Alethia Biotherapeutics Inc. Utilizarea concomitentă a unui inhibitor al clusterinei cu un inhibitor al EGFR pentru tratamentul cancerului

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721237A (en) * 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US5646042A (en) * 1992-08-26 1997-07-08 Ribozyme Pharmaceuticals, Inc. C-myb targeted ribozymes
US5417978A (en) * 1993-07-29 1995-05-23 Board Of Regents, The University Of Texas System Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
WO1995017507A1 (en) * 1993-12-23 1995-06-29 Biognostik Gesellschaft für Biomolekulare Diagnostik mbH ANTISENSE NUCLEIC ACIDS FOR THE PREVENTION AND TREATMENT OF DISORDERS IN WHICH EXPRESSION OF c-erbB PLAYS A ROLE
AUPM672594A0 (en) * 1994-07-08 1994-08-04 Royal Children's Hospital Research Foundation A method for the prophylaxis and/or treatment of proliferative and/or inflammatory skin disorders
US5789389A (en) * 1995-03-17 1998-08-04 Board Of Trustees Of University Of Illinois BCL2 derived genetic elements associated with sensitivity to chemotherapeutic drugs
US5855911A (en) * 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
DK0882061T3 (da) * 1996-02-14 2004-09-27 Isis Pharmaceuticals Inc Sukkermodificerede gapped oligonukleotider
US5910583A (en) * 1996-11-04 1999-06-08 Duke University Antisense oligonucleotides against ERBB-2
US6383808B1 (en) * 2000-09-11 2002-05-07 Isis Pharmaceuticals, Inc. Antisense inhibition of clusterin expression
US6335194B1 (en) * 1998-09-29 2002-01-01 Isis Pharmaceuticals, Inc. Antisense modulation of survivin expression
US6172216B1 (en) * 1998-10-07 2001-01-09 Isis Pharmaceuticals Inc. Antisense modulation of BCL-X expression
NZ513757A (en) * 1999-02-26 2004-12-24 Univ British Columbia Antisense oligonucleotides to inhibit TRPM-2 expression and delay androgen independance in prostatic tumour cells
US6900187B2 (en) * 1999-02-26 2005-05-31 The University Of British Columbia TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications
US5998148A (en) * 1999-04-08 1999-12-07 Isis Pharmaceuticals Inc. Antisense modulation of microtubule-associated protein 4 expression
US7569551B2 (en) * 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
WO2002097114A2 (en) * 2001-05-29 2002-12-05 Sirna Therapeutics, Inc. Nucleic acid treatment of diseases or conditions related to levels of ras, her2 and hiv
WO2003062421A1 (en) * 2002-01-17 2003-07-31 The University Of British Columbia Bispecific antisense olignucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same
AU2003237790A1 (en) * 2002-05-14 2003-12-02 Baylor College Of Medicine Small molecule inhibitors of her2 expression
US7285541B2 (en) * 2002-08-21 2007-10-23 The University Of British Columbia Treatment of melanoma by reduction in clusterin levels
KR101117673B1 (ko) * 2002-08-21 2012-03-07 더 유니버시티 오브 브리티쉬 콜롬비아 암-관련 단백질을 표적으로 하는 알엔에이아이 프로브
CA2520518A1 (en) * 2003-04-18 2004-10-28 The University Of British Columbia Method for treatment of angiogenic disorders
US20040220131A1 (en) * 2003-04-18 2004-11-04 The University Of British Columbia Method for treatment of cancerous angiogenic disorders
US8710020B2 (en) * 2004-04-02 2014-04-29 The University Of British Columbia Clusterin antisense therapy for treatment of cancer
SI1814595T1 (sl) * 2004-11-23 2014-06-30 The University Of British Columbia Zdravljenje raka s kombinacijo sredstva, ki moti EGF signalno pot, in oligonukleotida, ki zniĹľuje nivoje klusterina

Also Published As

Publication number Publication date
AU2005309274B2 (en) 2011-07-21
EP1814595A4 (en) 2009-04-15
JP4980919B2 (ja) 2012-07-18
DK1814595T3 (da) 2014-03-31
EP1814595B1 (en) 2014-01-08
US20080014198A1 (en) 2008-01-17
CA2584646A1 (en) 2006-06-01
US20110142827A1 (en) 2011-06-16
WO2006056054A1 (en) 2006-06-01
PL1814595T3 (pl) 2014-08-29
EP1814595A1 (en) 2007-08-08
PT1814595E (pt) 2014-04-02
JP2008520591A (ja) 2008-06-19
CA2584646C (en) 2015-11-03
SI1814595T1 (sl) 2014-06-30
AU2005309274A1 (en) 2006-06-01

Similar Documents

Publication Publication Date Title
US8252765B2 (en) Treatment of cancer by inhibition of IGFBPs and clusterin
US20110142827A1 (en) Treatment of cancer with a combination of an agent that perturbs the egf signaling pathway and an oligonucleotide that reduces clusterin levels
JP2010530754A (ja) ヒトＥＧＦＲ−ｓｉＲＮＡを含む組成物および使用方法
ES3054091T3 (en) Asymmetric sirna for inhibiting expression of male pattern hair loss target gene
Tokunaga et al. Potent effect of adenoviral vector expressing short hairpin RNA targeting ribonucleotide reductase large subunit M1 on cell viability and chemotherapeutic sensitivity to gemcitabine in non-small cell lung cancer cells
WO2017138925A1 (en) Antitumour combinations of antisense oligonucleotides and anticancer agents
JP2009518022A (ja) 抗ミオシンＶａｓｉＲＮＡおよび皮膚の脱色
US11110182B2 (en) Multifunctional RNA nanoparticles and methods for treating cancer and therapeutic resistant cancer
Wang et al. shRNA-mediated silencing of Y-box binding protein-1 (YB-1) suppresses growth of neuroblastoma cell SH-SY5Y in vitro and in vivo
Hu et al. Stable RNA interference of ErbB-2 gene synergistic with epirubicin suppresses breast cancer growth in vitro and in vivo
CA3143996A1 (en) Methods and compositions for the treatment of cancer
KR102234957B1 (ko) shRNA와 항-EpCAM 항체를 포함하는 바이러스 복합체 및 그의 용도
Seraj et al. Cytoplasmic expression of EGFR shRNA using a modified T7 autogene-based hybrid mRNA/DNA system induces long-term EGFR silencing and prolongs antitumor effects
CN101821410B (zh) 印迹位点调节物兄弟(boris)的基因沉默
TW201932123A (zh) 包含微小rna及其衍生物作為活性成分之藥物組成物
KR20070101610A (ko) Ａｎｔ２ 유전자의 발현을 억제하는 작은 간섭 ｒｎａ를이용한 암 유전자 치료 및 항암제 내성 극복방법
DK2257299T3 (en) Modulation of SRPX2-mediated angiogenesis
WO2006016574A1 (ja) ＲＮＡｉを利用した抗腫瘍剤
HK40130369A (zh) 用於治疗癌症的多核苷酸组合物和方法
WO2024003350A1 (en) Combination therapy for melanoma
JP2004350607A (ja) テロメレース阻害剤
KR20200118931A (ko) 저산소 환경에서 유발되는 암의 전이 억제용 조성물
KR20200018071A (ko) 세포질 내 shRNA의 지속적 발현을 위한 변형된 pT7/T7 폴리머라제 시스템 및 이를 포함하는 리포좀 전달체